✨ Free AI Report
PaxMedica, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research PaxMedica, Inc.
Company Research

PaxMedica, Inc.: Business Overview, Financials & Competitive Analysis

PaxMedica is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for neurologic disorders. Its lead product PAX-101, an IV formulation of suramin, is in Phase 3 trials for a...

Analyst-debate audio for PaxMedica, Inc.

AskCyborg analysts argue the bull and bear cases for PaxMedica, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
3/ 10Challenged

Cyborg Score thesis

High-risk clinical-stage biotech with potentially significant upside if Phase 3 trials succeed, but currently facing severe...

Read the full analyst-debate transcript →
Industry Biopharmaceutical / Clinical-Stage Drug Development
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest PaxMedica, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

PaxMedica, Inc. Overview

Pro stress-test →

PaxMedica is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for neurologic disorders. Its lead product PAX-101, an IV formulation of suramin, is in Phase 3 trials for autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, and other neurological conditions.

Strategic Profile

Pro stress-test →

The company was formerly known as Purinix Pharmaceuticals and rebranded to PaxMedica in April 2020. PaxMedica listed on NASDAQ in August 2022, pursuing specialized immunological and neurological drug development with a focus on rare and unmet medical needs in neurodevelopmental disorders.

Competitive Landscape

Pro stress-test →

PaxMedica competes in the rare neurological disease biotech space against larger players like Biohaven, Sage Therapeutics, and other autism/neurological disorder specialists. The company's unique anti-purinergic approach and multi-indication pipeline provide differentiation, though financial constraints limit competitive positioning.

Industry Context

PaxMedica, Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development.

Key facts

Founded: 2018 · Headquarters: Tarrytown, New York, US · Market cap: $12.6K

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on PaxMedica, Inc..

  • PAX-101 targets multiple high-unmet-need indications including autism spectrum disorder and long COVID-19 syndrome
  • Company currently trades on OTC Markets rather than NASDAQ despite earlier IPO listing
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • April 2024Company responded to emergency request for IV Suramin with commitment to provide immediate access to PAX-101
  • August 2022PaxMedica completed NASDAQ IPO listing 1.5 million shares
  • +1 moreTrack every material event for PaxMedica, Inc. as it happens. Explore monitoring →
Get alerted when PaxMedica, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Sage TherapeuticsCNS-focused biopharmaceutical company→Biohaven PharmaceuticalsRare neurological disorder treatment focus→Akcea TherapeuticsNeurological and neuroinflammatory disease focus→

Compare PaxMedica, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

PaxMedica, Inc. operates in Biopharmaceutical / Clinical-Stage Drug Development. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biopharmaceutical by Cyborg Score

Browse Biopharmaceutical / Clinical-Stage Drug Development research →
NEW · MCP server

Ask your AI assistant about PaxMedica, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare PaxMedica, Inc. and its top competitor on Cyborg Score”
“What did PaxMedica, Inc. do this quarter?”
“Is PaxMedica, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does PaxMedica, Inc. do?+
PaxMedica is a clinical stage biopharmaceutical company focused on developing anti-purinergic drug therapies for neurologic disorders. Its lead product PAX-101, an IV formulation of suramin, is in Phase 3 trials for a...
What is PaxMedica, Inc.'s Cyborg Score?+
PaxMedica, Inc. has a Cyborg Score of 3/10 (Challenged). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are PaxMedica, Inc.'s main competitors?+
Named competitors include Sage Therapeutics, Biohaven Pharmaceuticals, Akcea Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full PaxMedica, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the PaxMedica, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track PaxMedica, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biopharmaceutical research

Companies in the same sector and named competitors, ranked by Cyborg Score.

9Eli Lilly and Company8argenx SE8Ascendis Pharma A/S8Avidity Biosciences, Inc.8BeOne Medicines AG8Celltrion, Inc.8Corcept Therapeutics Incorporated8Insmed Incorporated8Roivant Sciences Ltd.8Terns Pharmaceuticals, Inc.Top companies in Biopharmaceutical by Cyborg Score